Europe
MorphoSys AG presented data from the primary analysis of the ongoing single-arm phase 2 clinical trial known as L-MIND in an oral presentation at the 15th International Conference on Malignant Lymphoma in Lugano, Switzerland.
In a statement, WHO said it was discontinuing two guidelines that have been in place since 2011 and 2012 “in light of new scientific evidence that has emerged since the time of their publication” regarding the dangers of opioid abuse.
Two well-known scientists, Margaret Hamburg, co-chair of the WHO’s international advisory committee on human genome-editing, and Victor Dzau, president of the U.S. National Academy of Medicine, told STAT in separate interviews this weekend that they were extremely concerned about Denis Rebrikov’s plans.
The technologies developed by LAB10x will be applied to generate and analyze “anonymized” patient data sets to improve patient outcomes and accelerate medical research and pharmaceutical R&D.
The board of directors of Medtronic plc approved an 8 percent increase in its quarterly cash dividend, raising the quarterly amount to $0.54 per ordinary share.
Ongoing pivotal Phase II clinical trial of ADCT-402 in patients with relapsed or refractory diffuse large B-cell lymphoma anticipated to complete enrollment in third quarter of 2019
Galapagos NV announces a share capital increase arising from warrant exercises.
Plenty of biopharma companies released results from clinical trials last week. Here’s a look at the top stories.
Allergan announced that the U.S. Food and Drug Administration has approved its wrinkle treatment Botox for children with upper limb spasticity. The news comes just days after rumors that the company may break up.
Lonza reports restated 2018 financials for sales, CORE EBITDA and CORE EBIT
PRESS RELEASES